SCHEMBL11909211

SCHEMBL11909211

Cc1ccc(-c2ccc(N)c(C(=O)O)n2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.50
CCR5 P51681 1/20 0.50
CCR8 P51685 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
MAP2K3 P46734 2/20 0.43
P4HA1 P13674 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
METAP2 P50579 1/20 0.39
NOS3 P29474 1/20 0.39
NOS2 P35228 1/20 0.39
ATR Q13535 2/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2A6 P11509 1/20 0.38
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
MAP4K1 Q92918 1/20 0.36
GRM5 P41594 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11907535 0.81 MAP2K3 (0.43) MAP2K3P4HA1P4HTMATRMAPT
SCHEMBL11908996 0.81 MAP2K3 (0.43) MAP2K3P4HA1P4HTMATRMAP4K1
SCHEMBL11908336 0.81 ATR (0.42) MAP2K3P4HA1P4HTMATRKDM4E
SCHEMBL11909990 0.81 MAP2K3 (0.40) MAP2K3P4HA1P4HTMCYP3A4MAP4K1
SCHEMBL11909201 0.80 ATR (0.43) MAP2K3P4HA1P4HTMATRKDM4E
SCHEMBL11906982 0.79 MAP2K3 (0.44) MAP2K3P4HA1P4HTMATRCYP3A4
SCHEMBL11907071 0.79 CCR1 (0.50) CCR1CCR5CCR8MAP2K3P4HA1
SCHEMBL11907922 0.78 KMT2A (0.45) MAP2K3P4HA1P4HTMMAPTRAB9A
SCHEMBL11908134 0.76 CCR1 (0.52) CCR1CCR8MAP2K3METAP2NOS3
SCHEMBL11907066 0.76 MAP2K3 (0.51) CCR1CCR5CCR8MAP2K3P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 CCR1 4514/4885CCR5 4243/4885CCR8 4622/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 CCR1 4514/4885CCR5 4243/4885CCR8 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.